国产伊立替康联合替加氟静脉滴注治疗晚期结直肠癌的有效性及安全性评价  

Clinical observation and safety evaluation of domestic irinotecan combined with tegafur on patients with advanced colorectal carcinoma

作　　者：马娟[1] 莫波[1] 闵春明[1] 

机构地区：[1]湖北医药学院附属人民医院肛肠外科,湖北十堰442000

出　　处：《实用药物与临床》2014年第3期319-321,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨国产伊立替康联合替加氟对晚期结直肠癌患者的疗效及其安全性。方法选择2008年4月至2011年12月我院收治的晚期结直肠癌患者49例,给予国产伊立替康180 mg/m2,d1,静脉滴注;替加氟15 mg/kg,d1～d5,静脉滴注,以21 d作为1个周期。结果对49例患者进行疗效评价,CR 1例(2.0%),PR 24例(49.0%),SD 10例(20.4%),PD 14例(28.6%),总有效率为51.0%,临床获益率为71.4%。中位疾病进展时间为8.1个月,中位患者生存期为14.5个月。主要的不良反应有:白细胞减少23例(46.9%)、腹泻20例(40.8%)、恶心呕吐16例(32.6%)、肝功能异常15例(30.6%),主要是Ⅰ～Ⅱ度不良反应。结论国产伊立替康联合替加氟静脉滴注治疗晚期结直肠癌,临床获益率较高,并且不良反应患者可耐受,是一种较为有效、安全的治疗方案,值得临床上推广使用。Objective To explore the efficacy and safety of domestic irinotecan combined with tegafur on pa- tients with advanced colorectal carcinoma. Methods 49 cases of advanced colorectal cancer patients from April 2008 to December 2011 in our hospital were chosen, all patients were given domestic irinotecan 180 mg/m2 , dl, intravenous infusion ;tegafur 15 mg/kg, dl -d5, intravenous infusion, 21 days as a cycle. Results 49 patients were evaluated by CR 1 case （2.0%）,PR24 cases （49.0%）,SD 10 cases （20.4%）,PD 14 cases （28.6%）,the total effective rate was 51.0% and clinical benefit rate cases was 71.4%. The median time to progression was 8. 1 months, median surviv- al was 14. 5 months. The main adverse reactions were：leukopenia 23 cases （46. 9% ） , diarrhea 20 cases （40. 8% ） , nausea and vomiting 16 cases （32. 6% ） ,abnormal liver function 15 cases （30. 6% ） ,mainly were degree I -Ⅱ ad- verse reactions. Conclusion Domestic irinotecan combined with tegafur intravenous treatment for advanced colorectal cancer has higher clinical benefit rate, and adverse reactions in patients are tolerated,it is an effective and safe treatment option, worthy of clinical spreading use.

关 键 词：伊立替康 替加氟 晚期结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]